US Stock Market Closed

Dashboard

Precigen, Inc. (PGEN)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

B

Industry Comparison

H

Management & Equity

B

Analyst Opinion

H

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

About

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The firm focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. It operates through the following segments: PGEN Therapeutics, ActoBio, MBP Titan, Trans Ova and All Other. The PGEN Therapeutics segment is advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders and infectious diseases. The ActoBio segment involves in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The MBP Titan segment comprises of Methane Bioconversion Platform, and associated technologies, personnel, and facilities The Trans Ova segment includes provides advanced reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

CEO

Helen Sabzevari

Employees

857

Industry

Agrochemical Products

Sector

Materials

Headquarters

Germantown

Exchange

NASDAQ

Summary Stats

Market Cap

457M

Revenue

75.9M

Net Income

25.5M

EPS

$0.13

Price-to-Earnings

14.3

Price-to-Book

3.21

Debt-to-Equity

0.82

News

Analyst Ratings

Price targets projected by 3 analysts

High

$13.00

Average

$9.00

Low

$6.00

Ratings calculated by 3 analysts

Buy

2

Hold

1

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q3 2022

Last Earnings

Above by $0.10

Actual

-$0.04 +71.4%

Consensus

-0.14

Report Date

Year Ago

-0.15

Year Ago Change %

Up 73%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites